Upregulation of p16INK4A and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours by Yoshida, T et al.
Upregulation of p16
INK4A and Bax in p53 wild/p53-overexpressing
crypts in ulcerative colitis-associated tumours
T Yoshida*,1, N Matsumoto
1, T Mikami
1 and I Okayasu
1
1Department of Pathology, Kitasato University School of Medicine, 1-15-1, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
In ulcerative colitis (UC)-associated tumours, p53 gene mutations and p53 protein overexpression are frequently found in early
stages, but the two types of alteration do not always coincide. To clarify this discrepancy, p53 mutations and expression of
p53-associated molecules were analysed in UC-associated dysplasias by a combination of microdissection, polymerase chain reaction-
direct sequencing and immunohistochemistry at the single crypt level. Mismatch of p53 protein overexpression (þ)/mutation ( )o r
p53 overexpression ( )/gene mutation (þ) was found in nine crypts in regenerative mucosa (19 crypts), in 27 in low-grade dysplasia
(41), in one in high-grade dysplasia (5) and in 12 in invasive carcinomas (17). Regarding these mismatched crypts of the first type,
significant increase in p16
INK4A and Bax expression was found. The Ki-67 labelling index was depressed in such p53-diffusely positive
lesions with the wild-type p53 gene, compared to their p53-diffusely positive and mutant type counterparts. p16
INK4A was
upregulated indirectly as part of the negative feedback, and increase in Bax, directly controlled by wild-type p53, indicates
upregulation of apoptosis. No significant relation with p53-related gene products was detected with the p53 protein overexpression
( )/p53 mutation (þ) mismatch. Therefore, a tumorigenesis pathway independent of p53 dysfunction appears to exist in association
with ulcerative colitis.
British Journal of Cancer (2004) 91, 1081–1088. doi:10.1038/sj.bjc.6602050 www.bjcancer.com
Published online 3 August 2004
& 2004 Cancer Research UK
Keywords: ulcerative colitis; dysplasia; p53 gene mutation; p53 overexpression
                                             
With longstanding ulcerative colitis (UC), dysplasias and carci-
nomas develop frequently, so that clinical surveillance of affected
individuals by periodic endoscopic screening and random biopsy
of colorectal mucosa is advisable (Blackstone et al, 1981; Collins
et al, 1987; Lennard-Jones et al, 1990). Compared to the sporadic
carcinoma case, p53 gene mutations are more frequent in early
stages of tumorigenesis, being found in low-grade dysplasia (LGD)
or non-neoplastic regenerative mucosa with ulcerative colitis
(Chaubert et al, 1994; Holzmann et al, 1998; Takaku et al, 2001).
Dysplasias and carcinomas associated with UC tend to develop as
multiple and superficially extended lesions called DALM (dys-
plasia-associated lesion or mass) (Blackstone et al, 1981; Collins
et al, 1987; Lennard-Jones et al, 1990; Okayasu et al, 1993).
Furthermore, DALMs appear to be frequent in areas of more active
inflammation. Therefore, a chronic inflammation – dysplasia –
carcinoma sequence has been proposed.
Alterations of the p53 gene, frequent in late-stage sporadic
colorectal carcinomas (Fearon and Vogelstein, 1990), have been
reported in UC-based dysplasia, as analysed in terms of genetic
instability (Willenbucher et al, 1999), chromosomal alterations
(Willenbucher et al, 1997; Aust et al, 2000) and polymerase chain
reaction (PCR)-single strand conformational polymorphism
(SSCP) (Yin et al, 1993). Particularly, p53 mutations have been
reported to be early events detected by indirect methods, such as
loss of heterozygosity (LOH) (Brentnall et al, 1994) and PCR-SSCP
(Holzmann et al, 1998). As it is important to identify single crypt
level mutations to understand UC-associated tumorigenesis, we
surveyed the whole coding region of p53 for mutations of single
crypts within lesions, using our novel method of microdissection
from serial histologic sections (Yoshida et al, 2003). We found p53
gene mutations in LGD and even in regenerative crypts of
longstanding UC as well as high-grade dysplasia (HGD) and
invasive carcinoma, but they did not always coincide with protein
overexpression. Therefore, to clarify mechanisms underlying this
discrepancy, mutations and p53-related, and expression of, cell
cycle-related gene products (p53, p21
Cip1, p27
Kip1, p16
INK4A, Mdm2,
p14
ARF, Bax, Ki-67) were analysed at the single crypt level in UC-
associated dysplasia and carcinomas by a novel combination of
microdissection, PCR-direct sequencing and immunohistochem-
istry (IHC). The results provided evidence of a novel pathway for
UC-associated tumorigenesis, involving upregulation of p16
INK4A
and Bax, which may be independent of p53 dysfunction.
MATERIALS AND METHODS
Histopathological Analysis
In total, 10 cases of long-term UC (21–64 years old, duration of
6–20 years) were selected. For comparison, 13 sporadic colorectal
adenocarcinoma cases, excluding hereditary nonpolyposis color-
ectal carcinomas, were chosen, and cancer lesions and samples of
normal mucosa at least 2cm distant were subjected to analysis.
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of single crypts
Serial deparaffinised sections of formalin-fixed and paraffin-
embedded materials for microdissection, hematoxylin–eosin
(HE) staining and p53 immunostaining were prepared as described
previously (Yoshida et al, 2003). Briefly, from a total of 15 serial
4mM-thick histologic sections, five were applied for microdissec-
tion and the remainder for HE and IHC (Figure 1). Tissues from
single crypts were microdissected manually, and DNA was
extracted by a conventional method. The whole coding region
of p53 (exons 2–11) was amplified by nested PCR, and DNA
sequences were analysed in forward and reverse directions with
the aid of an auto sequencer (ABI310 Genetic Analyser, PE Applied
Biosystems, Foster City, CA, USA).
Antibodies
Anti-p53 (DO-7; Novocastras Lab. Ltd, Newcastle, UK; diluted
 300), anti-p27
Kip 1 (Transduction Laboratory, Lexington,
Kentucky, USA;  300), anti-p21
Cip1 (Oncogene Research Pro-
ducts, Boston, MA, USA;  300), anti-p16
INK4A (C-20, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA;  250), anti-
p14
ARF (FL-132, Santa Cruz Biotechnology;  200), anti-Mdm2
(SMP 14, DAKO, Copenhagen, Denmark;  500), anti-Bax
(Transduction Laboratories;  300) and anti-Ki-67 antibodies
(MIB-1, DAKO;  300) were applied for IHC.
Immunohistochemistry
Immunohistochemistry was performed using a combination of
the standard streptoavidin–biotin–peroxidase complex (LSAB2
system, DAKO, Copenhagen, Denmark) method with antigen
retrieval, as described in our previous report (Yoshida et al, 2003).
Faint nuclear counterstaining was achieved with methyl green.
Immunopositivity for p53 in crypts was defined as: positive
staining of the whole crypt, þþ; positive staining of the lower
half of the crypt, þ; scattered, 7; and negative,  , modifying the
previously described method (Baas et al, 1994). Immunopositive
cells for all markers (labelling indices) were counted or scored for
each individual crypt. Scoring of Bax expression was performed
by multiplying the intensity (0–3) and area (0–3). Positivity for
other molecules was calculated as percentages of positive cells out
of 1000 cells.
Statistical significances were analysed by Fisher’s PLSD test,
utilising StatView software (version 5.0).
Western blotting
For confirmation of IHC, Western blotting of Bax and p16
INK4A
was performed for representative lesions (sporadic colon cancers
and normal colonic mucosa, seven cases; UC-associated invasive
carcinomas and regenerative mucosa, two cases). Aliquots of
100mg of normal mucosal and carcinoma tissue were lysed in 30ml
of phospholysis buffer (Han et al, 1996). In total, 30mg of total
cell lysate were subjected to 15% SDS–PAGE, and transferred to
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Figure 1 (A) The strategy for the microdissection, IHC and PCR-direct
sequencing. After mapping of lesions by microscopic observation, 15 serial
sections were prepared from each block. The fourth section in each series
was stained for HE, and the fifth was devoted to p53 IHC. Sections from
the first to third and sixth to eighth were used for microdissection and PCR
amplification of the entire coding region of p53. Remaining sections were
used for IHC of Mdm2, p14
ARF, p16
INK4A, p21
Cip1/Waf1, p27
Kip1, Ki-67 and
Bax, respectively. (B,C) Examples of LGD crypts (B) and UC-Ca lesions
(C) selected for microdissection. Serial sections with HE and p53
immunostaining are shown on the left-hand side. Meyer’s hematoxylin
staining before and after microdissection in same sections are shown on the
right hand side. No mutations of p53 were found in (B). Mutation in codon
248 was found in (C) shown in partial electrophoregrams of forward and
reverse sequencing of p53 exon 7. Red stars indicate the mutated
nucleotides.
Table 1 Relation of p53 mutation to p53 protein overexpression in
single crypts
Histology crypts
a
p53
mutations
p53 protein accumulations
(wild/mutant)
b
  +/  ++ +
UC
REG 19 8/19 (42.1%) 14 (8/6) 1 (0/1) 1 (0/1) 3 (3/0)
LGD 41 14/41 (38.1%) 16 (8/8) 2 (1/1) 8 (7/1) 15 (11/4)
HGD 5 5/5 (100%) 1 (0/1) 0 1 (0/1) 3 (0/3)
Inv. Ca 7
c 3/7 (42.9%) 3 (2/1) 0 0 4 (2/2)
Non-UC
Normal 7 0/7 (0%) 5 (5/0) 2 (2/0) 0 0
Inv. Ca 13
c 5/13 (38.5%) 2 (1/1) 2 (2/0) 1 (1/0) 8 (4/4)
aNumbers of genetically analysed crypts are shown.
bp53 protein accumulations are
classified into four categories:  ¼no positive staining cells;  /+¼scattered staining
in the crypt (REG, LGD, HGD) or positive for less than 25% (invasive carcinoma);
+¼positive in the lower half of the crypt (REG, LGD, HGD) or positive for 25–75%
(invasive carcinoma); ++¼positive in the whole crypt (REG, LGD, HGD) or positive
for more than 75% (invasive carcinoma). Numbers in parentheses show wild-type
crypts (lesions) vs mutant type crypts (lesions).
cIn invasive carcinoma from UC and
non-UC, the number shows the analysed lesions. REG¼regenerative epithelium;
LGD¼low-grade dysplasia; HGD¼high-grade dysplasia; UC¼ulcerative colitis; Inv.
Ca.¼invasive carcinoma.
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Figure 2 Morphology and immunohistochemical findings for UC-associated lesions. (A–D) HE, p53, p21
Cip1, p21
Kip1, p16
INK4A, p14
ARF, Mdm2, Bax and
Ki-67 staining in semiserial sections (A: REG with wild p53 gene, B: LGD with mutant p53 gene, C: HGD with mutant p53 gene, D: invasive carcinoma with
mutant p53 gene).
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Little Chalfont, Buckinghamshire, UK). Immunoblotting was
carried out with the ECL chemiluminescence system (Amersham
Pharmacia Biotech) with 500  diluted anti-p16
INK4A, 750 
diluted anti-Bax and 5000  diluted anti-b-actin antibodies
(AC-15, Sigma, Saint Louis, MO, USA) as the primary, and anti-
rabbit immunoglobulin–HRP (Amersham Pharmacia Biotech),
or anti-mouse immunoglobulin-HRP (DAKO) as the secondary
antibodies.
Reverse transcription–quantitative PCR
Real-time quantitative PCR analysis for p16
INK4A was performed
using the ABI PRISM 7700 Sequence Detection System and
software (PE Applied Biosystems, Inc., Foster City, CA, USA).
Total RNA from specimens of UC-associated carcinomas and
nontumour mucosa were extracted with TRIzol reagent (Invitro-
gen). cDNA was synthesised from 3mg of total RNA with TaqMan
Reverse Transcription Reagents (PE Applied Biosystems). p16
INK4A
and primer and probe set were purchased (Pre-Developoed
TaqMan Assay Reagents; PE Applied Biosystems, Cat.No.
4319445T). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as endogenous control to standardise for the amount
of RNA in each reaction (TaqMan GAPDH control reagents; PE
Applied Biosystems). cDNA was amplified using the TaqMan
Universal PCR Master Mix (PE Applied Biosystems) according to
the manufacturer’s instructions on an ABI PRIM 7700 Sequence
Detector. Each reaction was performed in a 25ml volume contain-
ing 2ml out of 20ml of reverse transcription reaction mixture. The
cycling conditions were 501C for 2min and 951C for 10min,
followed by 50 cycles of 951C for 15s, and 601C for 1min. All
samples were amplified in triplicate. Copies (10–10
8) of GAPDH
plasmid were amplified to generate standard curves to relate
threshold to log input amount of template. The standard curve of
the GAPDH amplification was obtained as y¼(slope) logxþ(Y-
intercept). The threshold cycles (CT’s) for GAPDH and p16
INK4A
of nontumour mucosa (N) and UC carcinoma (T) were calculated.
From the standard curve, amounts of DNA at the threshold cycle
were calculated as ðcDNAÞ¼ð cDNA0Þð1 þ eÞ
CT (e; amplification
efficiency¼10
 1/(slope) 1), and the cDNA ratio of tumour against
normal tissue was calculated as follows: RT/N¼(1þe)CT
T/(1þe)CT
N.
RESULTS
p53 mutations and p53 overexpression (Table 1)
The strategy of the combination of microdissection–PCR-direct
sequencing and IHC is schematically illustrated in Figure 1A.
Examples of the microdissection and sequencing data are shown
in Figure 1B and C. Both p53 gene mutations and protein
a : P < 0.01
b : P < 0.051
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Figure 3 Immunopositivity for p53-related molecules in UC-associated lesions. Percentages or scores for immunopositivity are shown separately for the
upper (open bars) and lower (gray bars) halves of the crypts. Data for UC-associated invasive carcinomas (UC-Ca) are shown in black bars and sporadic
invasive carcinomas (sp-Ca) in hatched bars. Vertical lines show 1 s.d. A: p21
Cip1, B: p27
Kip1, C: p16
INK4A, D: p14
ARF, E: Mdm2, F: Bax and G: Ki-67. (a)
Po0.01; (b) Po0.05 by Fisher’s PLSD test.
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yaccumulation were analysed in 19 REG, 41 LGD, five HGD, seven
UC-associated invasive carcinoma crypts or lesions. The former
were found by PCR–direct sequencing in 42.1, 38.1, 100 and 42.9%
of the cases, respectively. p53 protein accumulation was classified
into four categories on the basis of IHC findings (see the legend
of Table 1). Of the REG crypts, 73.7% (14 crypts out of 19) were
negative for p53 accumulation and 26.3% (five crypts) were
positive (þ/ , þ or þþ). For LGD, the figures were 39.0% (16
out of 41) and 61.0%; for HGD, 20% (one out of five) and 80%;
and for invasive carcinomas from UC, 42.9% (three lesions out of
seven) and 57.1% (four lesions). Both kinds of discrepancies
between p53 overexpression and gene mutations were apparent:
(1) p53 overexpression (þ)/gene mutation ( ), (2) p53 over-
expression ( )/gene mutation (þ). In REG, three crypts showed
the former (1) (15.8%) and six the latter (2) (31.5%), out of a total
of 19 crypts. Likewise, for LGD, there were 19 (46.3%) and eight
(19.5%) in 41 crypts; in HGD, only one crypt demonstrated a type
2 (20%) mismatch out of five crypts; in UC-associated invasive
carcinomas, the figures were two (28.6%) and one (14.3%); and
in non-UC-associated cancers, seven (53.8%) and one (7.7%).
Immunohistochemistry of p53-related gene products
(Figures 2–5)
Although p21
Cip1 was expressed mainly in the upper half of the
crypts in normal mucosa, REG, LGD and HGD, reduced expression
was seen in UC-associated and non-UC-associated invasive
carcinomas, the difference being significant (Figure 3A). p27
Kip1
expression was greater in the lower than in the upper half of the
crypt in normal, REG, LGD and HGD cases, and the expression
level increased with progression of lesions (Figure 3B). In UC-
associated invasive carcinomas, the expression was significantly
reduced as compared to HGD and sporadic colon cancers. The
expression of p21
Cip1 and p27
Kip1 demonstrated no significant
differences in relation to the p53 expression in normal, REG, LGD,
HGD mucosa (Figure 4A and B). Levels of p16
INK4A were
significantly increased in invasive carcinomas (UC-associated
and non-UC associated) compared to the both upper and lower
half of the crypts of normal and REG mucosa (Figure 3C). In the
lower half of the LGD crypts, expression was significantly higher
than in normal mucosa. Limited to normal, REG, LGD, HGD
mucosa, step-wise increase in p16
INK4A expression was seen with
p53 overexpression (Figure 4C). Dividing into categories with or
without genetic mutations of p53, mutant crypts with diffuse p53
overexpression had significantly decreased expression of p16
(Figure 5A).
With p14
ARF, no significant variation was detected (Figure 3D).
However, Mdm2 expression in regenerative mucosa was signifi-
cantly higher than in normal, LGD, HGD crypts and in UC-
associated and non-UC-associated invasive carcinoma lesions
(Figure 3E). The expression of p14
ARF and Mdm2 demonstrated
no significant relation with p53 levels (Figure 4D and E). With
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Figure 4 Immunopositivity of p53-related molecules compared to p53 overexpression in UC-associated dysplastic lesions and regenerative crypts.
Percentages or scores for immunopositivity are shown as in Figure 2. A: p21
Cip1, B: p27
Kip1, C: p16
INK4A, D: p14
ARF, E: Mdm2, F: Bax and G: Ki-67. Degrees
of p53 overexpression are shown as  , þ/ , þ and þþ, as described in Materials and methods. (a) Po0.01; (b) Po0.05 by Fisher’s PLSD test.
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yscoring for the intensity and areas of positive cells, there was a
tendency for Bax expression to increase along with progress of
histological features in both upper and lower crypts (Figure 3F).
The score was significantly higher in LGD than in normal or REG
mucosa (upper and lower crypt), in HGD than in normal mucosa
(lower crypt), in UC-associated invasive carcinoma than in upper
half of the normal or REG mucosa and in lower half of normal
mucosa, and in sporadic invasive carcinomas than in UC-
associated carcinomas. Bax expression was also significantly
higher in p53 þ or þþ crypts than in their p53  or þ/ 
counterparts (Figure 4F). Such increase was not seen in p53
mutant crypts with diffuse p53 overexpression (p53 þþ)
(Figure 5B). Cell cycling, as indicated by Ki-67 expression, was
increased along with the histological stage and the p53 expression
level in upper crypts (Figures 3G and 4G). Additionally, p53
mutant crypts with diffuse p53 overexpression showed signifi-
cantly higher Ki-67 labelling indices than wild-type crypts
(Figure 5C). Compared to the lower halves of crypts of REG or
LGD mucosa, cell cycling was increased in UC-associated invasive
carcinomas.
Bax and p16
INK4A expression by immunoblotting and
quantitative PCR (Figure 6)
By immunoblotting, increased expression levels of p16
INK4A
and Bax were evident in UC-associated invasive carcinoma tissue
as compared to UC-regenerative mucosa, correlating with
the immunohistochemical results. Increase of Bax and p16
INK4A
expression was also seen in sporadic invasive carcinomas (Bax,
four out of six examined cases; p16
INK4A, four out of six examined
cases), although the two did not well match each other. p53 gene
mutations in sporadic invasive carcinomas also did not coincide
with Bax and p16
INK4A expression.
Threshold cycles (CT’s) for p16 and GAPDH of nontumour
tissue of UC and UC-associated tumour were obtained by real-time
quantitative PCR. From the formula described in Materials and
methods, cDNA ratios of p16 (tumour vs normal tissue) and
GAPDH were 1371 and 8.456. Under the assumption that the
efficiency of reverse transcription was constant, the induction ratio
of mRNA of p16 (tumour vs normal tissue) is estimated 162.2 after
compensation for GAPDH induction.
DISCUSSION
As confirmed by the present study, p53 gene mutations and p53
protein overexpression in malignant neoplasms are not necessarily
concordant. In our previous report, although there was coin-
cidence in eight out of 20 cases of sporadic colorectal carcinoma,
mismatches were found in 11 cases (Yamashita et al, 2001). In
these lesions, we carefully sequenced in forward and reverse
directions to exclude technical errors to the best of our ability. The
possibility that a mutation outside the coding region could have
influenced the expression or function of p53 must also be borne
in mind. However, so far we examined, in the present study, three
(15.8%), 19 (46.3%) and 0, REG, LGD and HGD crypts of UC,
respectively, demonstrated overexpression despite a lack of any
mutation. In addition, six (31.5%), eight (19.5%) and one (20.0%),
respectively, had mutations but no overexpression. There are
possible explanations for this type of mismatch group. At least, as
the epitope of DO-7 used in immunostaining is amino-terminus of
p53, and the hot spot of p53 mutation is in the relatively carboxyl-
terminus, most (but not all, perhaps) of the mutant p53 could be
detected by DO-7. Although, the analysed crypt numbers for HGD
were rather small, making conclusions difficult, mismatches were
very prevalent in REG or LGD, early stages in UC-associated
tumorigenesis.
Since it is of interest to ascertain whether the molecular
mechanisms are dependent or independent of p53 or related
molecules in tumorigenesis, we analysed negative cell cycle
regulators, the cyclin-dependent kinase inhibitors p21
Cip1,
p27
Kip1 and p16
INK4A, the p53-related cell cycle regulators,
p14
ARF and Mdm2, a proapoptosis molecule, Bax, and a
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Figure 5 Immunopositivity of p16
INK4A, Bax and Ki-67 compared to p53
gene mutation and overexpression in UC-associated dysplastic lesions and
regenerative mucosa. Percentages or scores for immunopositivity are
shown as in Figure 2. Open bars are for p53-wild type (w) and hatched bars
for p53 mutated crypts (m). A: p16
INK4A, B: Bax and C: Ki-67. Degrees
of p53 overexpression are shown as  , þ/ , þ and þþ, as described
in Materials and methods. (a) Po0.01; (b) Po0.05 by Fisher’s PLSD test.
Bax
p16INK4A
-Actin
Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
NTN N N N N TT T T T
p53
mutation
UC-Ca-1
UC-Ca-2
Reg RegCa Ca
p53 IHC ++
++ + ––– – –
+/– ++ – ++ – + –
Sporadic colon cancer UC - cancer
Figure 6 Immunoblotting of p16
INK4A and Bax in representative sporadic
and UC-associated invasive carcinomas. Immunohistochemical expression
of p16
INK4A and Bax was confirmed by immunoblotting. p53 IHC, p53
overexpression analysed immunohistochemically in identical lesions; p53
gene mutations determined by PCR–SSCP and DNA sequencing; b-actin,
quantitative standard. Molecular weight marker (15k) is shown with p16
bands.
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and p27 are expressed in inverse correlation to the progression of
carcinomas, and p16 and p14 are known to be methylated in many
carcinoma cases. Mdm2 degrades p53 and thus keeps the
endogenous level of the protein low. Bax, the apoptosis-inducing
factor, has a p53-responsive element in its promoter region and
is induced by p53. In the present study, Mdm2 expression was
significantly increased only in regenerative crypts compared to
normal crypts, suggesting a positive role for p53 protein
degradation. We here revealed that, in UC-associated lesions,
p21 expression is significantly reduced in invasive carcinomas
compared to normal mucosa, and that p27 expression tends to
increase along with progression of dysplasia but is also
significantly decreased in later stages. This result suggests that in
dysplasia, p21 and p27 may provide a negative feedback against
progression, but that this is lost with onset of malignancy.
Although we did not find a significant difference in p14 with
progression from dysplasia to carcinoma, step-wise induction of
p16 was seen. This is an unexpected result in light of the previous
finding that p16 promoter methylation is frequent in UC-
associated dysplasia or carcinomas (Hsieh et al, 1998). While the
discrepancy remains to be clarified, increased p16 expression at
the protein level was also confirmed biochemically in UC-
associated carcinomas and sporadic carcinomas of colorectum in
the present study. Since the induction was also confirmed by real
time-PCR at mRNA level, the increased p16 expression suggested
to be due to increased transcription, and not to protein
stabilisation. Interestingly, increase of p16 expression in dysplasia
was accompanied by positive p53 overexpression of the wild-type
gene, whereas the expression level in dysplasia of mutant type was
significantly lower. Likewise, the Bax expression in p53-over-
expressed crypts was increased along with progression of
dysplasia, but only in lesions without any mutation. Since Bax is
a downstream effector of p53, this is reasonable. There are two
types of diffuse overexpression of p53, with a wild-type or mutant
gene status. The former can directly induce Bax, and may
indirectly induce p16 as part of the negative feedback system,
but the latter cannot. Therefore, in tumours with mutated p53,
failure of the p53 regulation system might be a key event for
tumorigenesis. On the other hand, without any mutation, the p53
system might be intact and dysfunction of other regulating
pathways is involved. Recently deregulation of the b-catenin and
Wnt signalling pathway has been reported to induce cell
proliferation when p14
ARF function is lacking (Damalas et al,
2001), and a possible relation of dysfunction of b-catenin with
UC-associated tumours has been reported (Walsh et al, 1999;
Mikami et al, 2000; Aust et al, 2001; Haq et al, 2001). Further study
of b-catenin and Wnt signalling pathways, concurrently with
genetic analysis of p53 should provide clues regarding this
question.
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